Dr. Berry provides care for people with amyotrophic lateral sclerosis (ALS).  He is  the director of the Massachusetts General Hospital (MGH) multidisciplinary amyotrophic lateral sclerosis (ALS) clinic and Chief of the Division of ALS and Motor Neuron Diseases. He has worked to better serve people with ALS by building the tools and team required to extend the reach of the MGH clinic team beyond the walls of the physical clinic.  The ALS House Call program and video televisit program are examples of exciting initiatives at the MGH ALS clinic.

Dr. Berry also works as an ALS researcher, designing, overseeing, and carrying out trials at MGH and centers across the country. His work is focused on the identification of markers of ALS in blood and spinal fluid, with an emphasis on markers of abnormal inflammation. He collaborates broadly with researchers around the globe on these biomarker efforts.  He is also actively working to develop mobile health and digital phenotyping methods to better understand ALS and hasten the development of new therapies, while reducing the burden of trial participation for people with ALS.

Dr. Berry is also the Associate Director of the MGH Neurological Clinical Research Institute (NCRI) and Director of the Partners Neurodegenerative Clinical Research Fellowship. He is a member of the Massachusetts ALS Registry team and CDC/ATSDR National ALS Registry and Biorepository Expert Panels. In addition, he is on the Executive Committee of the NEALS Consortium, a national organization for ALS clinical researchers, where he also leads the NEALS Biorepository and Technology in ALS subcommittee.